Free Trial
OTCMKTS:RGRX

RegeneRx Biopharmaceuticals (RGRX) Stock Price, News & Analysis

RegeneRx Biopharmaceuticals logo
$0.0014 0.00 (0.00%)
(As of 11/22/2024 ET)

About RegeneRx Biopharmaceuticals Stock (OTCMKTS:RGRX)

Key Stats

Today's Range
$0.0014
$0.0014
50-Day Range
N/A
52-Week Range
$0.00
$0.06
Volume
N/A
Average Volume
65 shs
Market Capitalization
$2,114.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Receive RGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RGRX Stock News Headlines

EIGRQ Eiger BioPharmaceuticals, Inc.
Regenerx Biopharmaceuticals Inc RGRXD
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Regenerx Biopharm In (RGRXD)
RGRX RegeneRx Biopharmaceuticals, Inc.
See More Headlines

RGRX Stock Analysis - Frequently Asked Questions

RegeneRx Biopharmaceuticals' stock was trading at $0.0012 on January 1st, 2024. Since then, RGRX stock has increased by 16.7% and is now trading at $0.0014.
View the best growth stocks for 2024 here
.

RegeneRx Biopharmaceuticals's stock reverse split on the morning of Monday, August 14th 2023. The 1-100 reverse split was announced on Monday, August 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that RegeneRx Biopharmaceuticals investors own include Fulcrum Therapeutics (FULC), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Biocept (BIOC) and Onconova Therapeutics (ONTX).

Company Calendar

Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:RGRX
Employees
3
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($2.40) per share

Miscellaneous

Free Float
1,319,000
Market Cap
$2,114.00
Optionable
Not Optionable
Beta
2.78
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:RGRX) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners